Drugs / LABAFENOGENE MARSELECOBAC
LABAFENOGENE MARSELECOBAC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04984525 | Jul → Dec 2021 | — | Synlogic | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04534842 | Aug 2020 → Oct 2022 | phenylketonuria | Synlogic | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LABAFENOGENE MARSELECOBAC | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314748 ↗ |
| Known as | Labafenogen marselecobac | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314748 ↗ |
| Known as | SYNB1934 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04534842 ↗ |
| Modality | Cell therapy | “live cells” NCT04984525 ↗ |
| Route | Oral | “15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934” NCT04534842 ↗ |